Search - tctmd.com

Displaying 461 - 480 of 593

Sort: Relevancy | Date

News Conference News ISC 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Todd Neale

February 24, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Daily News

American Heart Association Annual Stats: Yet Again, CVD Is the Leading Killer

Shelley Wood

January 26, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

Michael O'Riordan

January 05, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Daily News

High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds

Todd Neale

December 19, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Lipid Losses: National Data Show Drastic Drops in Total Cholesterol, Triglycerides, and LDL

Yael L. Maxwell

November 30, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Conference News AHA 2016

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

Todd Neale

November 13, 2016

News Daily News

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

Michael O'Riordan

November 13, 2016

News Daily News

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Michael O'Riordan

November 10, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Advertisement

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Alirocumab to Remain On Market While Companies Clash Over Patents

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

American Heart Association Annual Stats: Yet Again, CVD Is the Leading Killer

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

TCTMD’s Top 10 Most Popular News and Features for 2016

High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Lipid Losses: National Data Show Drastic Drops in Total Cholesterol, Triglycerides, and LDL

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content